Publication date: Mar 22, 2025
The recently proposed body-first and brain-first subtypes are classified based on the initial localization of α-synuclein inclusions. This study investigated plasma biomarkers and cerebral glucose metabolism characteristics in putative brain-first and body-first subtypes in PD subjects. PD patients without possible RBD (PD) (n = 58) and with possible RBD symptoms discovered before motor symptoms (PD) (n = 43) were recruited. Single-molecule array (SimoA) was used for measuring plasma biomarkers, including glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), Tau and phosphorylated-tau 181 (pTau-181). All participants underwent F-fluorodeoxyglucose (FDG) PET scans. Compared to PD patients, PD patients exhibited significantly increased plasma GFAP levels and reduced F-FDG uptake in cortical regions. Notably, plasma GFAP and NfL levels correlated with cerebral glucose metabolism in PD patients. Our study identified the association between plasma GFAP and NfL levels and cerebral glucose metabolism in PD patients. Further large-scale longitudinal studies are required.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Biomarkers | Biomarkers |
| Fluorodeoxyglucose | Body |
| Initial | Brain |
| Nfl | Cerebral |
| Parkinsons | Gfap |
| Glucose | |
| Metabolism | |
| Nfl | |
| Patients | |
| Pd | |
| Plasma | |
| Putative | |
| Rbd | |
| Subtypes | |
| Symptoms |
Semantics
| Type | Source | Name |
|---|---|---|
| pathway | REACTOME | Glucose metabolism |
| disease | MESH | Parkinson’s disease |
| disease | MESH | REM sleep behavior disorder |
| pathway | REACTOME | Metabolism |
| disease | MESH | Neurological Disorders |
| drug | DRUGBANK | Coenzyme M |